HRSA-22-154: Fiscal Year 2022 Accelerating Cancer Screening
Closed
This grant is closed. A newer notice from the same program is forecast: Fiscal Year (FY) 2027 Service Area Competition (SAC) (HRSA-27-009). Status: Expected deadline January 8, 2027. It is in our archive of Health Resources and Services Administration notices from 2022.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 10 awards worth $5.0 million in total. Applications closed on June 15, 2022.
From the official notice on Grants.gov, last changed May 4, 2022. Checked November 7, 2026.
- Total funding$5.0 million
- Expected awards10
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | May 4, 2022 |
|---|---|
| Deadline | June 15, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Organizations eligible for AxCS funding are Health Center Program operational (H80) grant award recipients12 that partner with an NCI-designated Cancer Center.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity for HRSA-funded health centers to apply for FY 2022 Accelerating Cancer Screening (AxCS) funding. AxCS funding will support health centers to increase equitable access to cancer screening and referral for care and treatment1 by enhancing patient education, case management, outreach, and other enabling services, in close partnership or coordination with National Cancer Institute (NCI)-designated Cancer Centers that will deploy outreach specialists and patient navigators for populations served by health centers. For more details, see Program Requirements and Expectations.
Who has won Health Center Program grants before
From fiscal 2021 to 2025, Health Center Program (93.224) awarded $21 billion across 4,197 grant awards, an average of $5.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Sun River Health, Inc. | New York | 4 | $103 million |
| Family Health Centers of San Diego Inc | California | 6 | $87.8 million |
| Yakima Valley Farm Workers Clinic | Washington | 3 | $84.5 million |
| Altamed Health Services Corporation | California | 5 | $82.6 million |
| Clinica Sierra Vista | California | 2 | $81.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-009, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-22-154 still open?
No. It closed on June 15, 2022. A newer notice is forecast: HRSA-27-009, expected deadline January 8, 2027.
Who can apply for Fiscal Year 2022 Accelerating Cancer Screening?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Fiscal Year 2022 Accelerating Cancer Screening?
Closed June 15, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $5.0 million in total across about 10 awards.
Who has won Health Center Program grants before?
The largest recipients over five fiscal years were Sun River Health, Inc., Family Health Centers of San Diego Inc, Yakima Valley Farm Workers Clinic. The program made 4,197 awards worth $21 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)